ESG News Review 11 — 17 January 2014

20 01 2014

Alstom appeared among the most praised companies last week, as it announced it would cease engaging sales consultants to ensure it “conducts business in a responsible way and strives to achieve the highest ethical standards”. Alstom is also calling for a target of more than 30% of renewable energy sourced in Europe by 2030. Hewlett-Packard […]

Pledge of $150m to fight neglected diseases

14 10 2010

Six pharmaceutical companies and several governments have pledged more than $150m in medicines and funding over five years to tackle some of the most neglected diseases. The debilitating illnesses — including leprosy, lymphatic filariasis and sleeping sickness — affect 1bn of the world’s poorest people, place a burden on health services, stunt children’s education and […]

Parachutes dorés : le Medef et l’Afep veulent une France exemplaire

6 10 2008

Le Medef a horreur des décisions de circonstance mais, cette fois, la pression politique est telle qu’il n’a plus le choix. Moins de deux ans après avoir émis des recommandations sur la rémunération des dirigeants, suite aux affaires Forgeard (EADS) et Zacharias (Vinci), l’organisation présidée par Laurence Parisot dévoile ce matin un « code de […]

The Humanitarian Sponsorship Charter

15 09 2008

Sanofi-aventis selects humanitarian sponsorship actions on the basis of 6 main criteria: Consistency: Prioritize thematic actions: health – solidarity – childhood in the field of prevention, education, training, hygiene, access to care, combating exclusion, disability, children’s traumas… Usefulness: Respond to the most basic needs that society handles inadequately today, especially for the most destitute populations. […]

Pharmas Challenged by Product Risk and Philanthropy Fatigue – Covalence Pharmaceutical Industry Report 2008

9 09 2008

Increased attention on product human risk and smaller media coverage of drug donations have challenged Pharmaceuticals’ ethical reputation last year, states a report published today by Geneva-based research firm Covalence — Covalence Pharmaceutical Industry Report 2008. The pharmaceutical industry dropped from the first to the third rank of Covalence all-time EthicalQuote ranking across 10 industries. […]

Big drug companies raided in EU probe

17 01 2008

European regulators raided some of the world’s biggest pharmaceutical companies yesterday in an inquiry into whether they conspired to keep up the price of drugs after patents expired. Pfizer, GlaxoSmithKline, AstraZeneca and Sanofi-Aventis were among those that confirmed they had been visited as part of a European Commission-led probe into delays in the launch of […]

Innovation et philanthropie dopent le marché des vaccins

8 01 2008

En 2007, le laboratoire américain Merck a supplanté Sanofi Aventis à  la tàªte du classement mondial des producteurs de vaccins. GlaxoSmithKline (GSK), qui talonnait Sanofi, se retrouve donc numéro trois. Sur les neuf premiers mois de 2007, Merck a réalisé 2,13 milliards d’euros de chiffre d’affaires, son dauphin Sanofi Aventis 2,12 milliards et GSK 1,9 […]

The Burden of Innovation – Covalence Pharmaceutical Industry Report 2007

29 08 2007

Pharmaceutical companies carry increasing ethical risks related to innovation, states a report released on 29 August 2007 by Geneva-based ethical reputation research firm Covalence, Covalence Pharmaceutical Industry Report 2007. These innovation-related risks deal with intellectual property rights, drug pricing, clinical trials, drug side-effects and transparency. In terms of ethical reputation, innovation seems to bring more […]

The Ethically Challenged: How Pharma Fares

31 05 2007

In these ethically challenging times, which drugmaker has its act together? Covalence, a research group based in Geneva that tracks ethical reputations, recently released its quarterly update in which various industrial sectors were examined. The firm compiles its rankings and charts by collecting reports – both positive and negative recent news – from the Internet […]

On The Trail Of A Cure: Reality And Rhetoric On Treating Malaria

22 03 2007

New treatments for malaria were developed in response to a resurgence of the disease in the 1990s.